U.S. Markets closed

Vermillion patent for predictive markers for ovarian cancer posted by USPTO

According to a post to the USPTO site dated March 4, Vermillion applied for a patent for methods for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided in the patent filing.